SCHEMBL2026412

SCHEMBL2026412

CC(C)OC(=O)N[C@H]1Cc2c(n(Cc3nccnc3N)c3ccc(C#N)cc23)C1

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ RET P07949 1/20 0.34
▸ RORC P51449 1/20 0.33
▸ SCARB1 Q8WTV0 3/20 0.33
▸ HTR3A P46098 1/20 0.33
▸ HRH1 P35367 1/20 0.33
▸ HTR6 P50406 1/20 0.33
▸ PTGDR2 Q9Y5Y4 2/20 0.32
▸ GPR119 Q8TDV5 1/20 0.32
▸ IRAK4 Q9NWZ3 3/20 0.31
▸ TNF P01375 1/20 0.31
▸ DRD2 P14416 1/20 0.31
▸ CCNC P24863 1/20 0.30
▸ CDK8 P49336 1/20 0.30
▸ CLK1 P49759 1/20 0.30
▸ CLK2 P49760 1/20 0.30
▸ CDK7 P50613 1/20 0.30
▸ CDK9 P50750 1/20 0.30
▸ IRAK1 P51617 1/20 0.30
▸ CLK4 Q9HAZ1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2022401 1.00 RET (0.34) RETRORCSCARB1HTR3AHRH1
SCHEMBL16493840 0.91 SCARB1 (0.35) RETRORCSCARB1HTR3AHRH1
SCHEMBL2024064 0.91 RORC (0.35) RETRORCSCARB1HTR3AHRH1
SCHEMBL2024062 0.91 RORC (0.35) RETRORCSCARB1HTR3AHRH1
SCHEMBL12640978 0.89 RET (0.32) RETHTR6PTGDR2DRD2
SCHEMBL2023485 0.89 HRH1 (0.35) RETRORCSCARB1HTR3AHRH1
SCHEMBL2023482 0.89 HRH1 (0.35) RETRORCSCARB1HTR3AHRH1
SCHEMBL1177774 0.88 HRH1 (0.35) RETRORCSCARB1HTR3AHRH1
SCHEMBL1177777 0.88 HRH1 (0.35) RETRORCSCARB1HTR3AHRH1
SCHEMBL16493847 0.87 HRH1 (0.38) RETRORCSCARB1HTR3AHRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2094658-B1 TETRAHYDROCYCLOPENTA[B]INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS LILLY CO ELI (US) 2011-12-21 — — EP disclosed
EP-2094658-B1 TETRAHYDROCYCLOPENTA[B]INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS LILLY CO ELI (US) 2011-12-21 — — EP disclosed
US-7968587-B2 Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators ELI LILLY AND COMPANY (US) 2011-06-28 — — US disclosed
US-7968587-B2 Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators ELI LILLY AND COMPANY (US) 2011-06-28 — — US disclosed
US-20100069404-A1 TETRAHYDROCYCLOPENTA[b] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS ELI LILLY AND COMPANY 2010-03-18 — — US disclosed
US-20100069404-A1 TETRAHYDROCYCLOPENTA[b] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS ELI LILLY AND COMPANY 2010-03-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069404-A1 TETRAHYDROCYCLOPENTA[b] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS AR, NR5A1, MUSK RET 2310/4885RORC 320/4885SCARB1 1045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback